Key facts
- It has raised $1.3M across 1 recorded rounds; the latest was Seed Round ($1.3M) in Dec 2024.
- Plexiform Bioscience has filed 2 Form Ds with the SEC since 2024, most recently Jul 2025 ($1.3M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Plexiform Bioscience
Funding rounds
1 roundsAbout Plexiform Bioscience
Operator of non-invasive retinal treatments intended to improve eye health. The company's platform focuses on innovative therapies that deliver targeted treatment directly to the retina through engineered eye drops, eliminating the need for frequent injections, enabling patients to have reduced discomfort by providing simple retinal disease treatment and improving accessibility to care.
- Sector
- Healthcare
- HQ
- Dover, DE, United States
- Founded
- 2024
- Website
- plexiformbio.com/
- Ownership
- Privately Held (backing)
Plexiform Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Plexiform Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Plexiform Bioscience in its N-PORT filings yet. We sweep new filings monthly.